nnc-55-0396 free base

NNC-55-0396 is a small molecule research compound that functions as a highly selective blocker of T-type calcium channels, specifically targeting the Cav3.1 and Cav3.2 subtypes. Developed by Novo Nordisk, it is a structural analog of mibefradil but exhibits significantly improved selectivity for T-type over L-type calcium channels. In laboratory studies, NNC-55-0396 has demonstrated a range of biological activities, including the inhibition of angiogenesis, induction of apoptosis in various cancer cell lines, and neuroprotective properties. It is widely utilized as a pharmacological tool to investigate the physiological and pathological roles of T-type calcium channels in neurological disorders and oncology research. The compound is available in both its free base form and as a dihydrochloride salt for improved solubility in aqueous media.

Other names

NNC 55-0396NNC55-0396NNC-55-0396(1S,2S)-2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthalenyl cyclopropanecarboxylate